Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective, investigator-initiated study of EXPAREL (bupivacaine liposome injectable suspension) to manage postsurgical pain following cesarean section (C-section) procedures

Next Previous
Trial Profile

A retrospective, investigator-initiated study of EXPAREL (bupivacaine liposome injectable suspension) to manage postsurgical pain following cesarean section (C-section) procedures

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Dec 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupivacaine (Primary) ; Ketorolac; Nalbuphine; Paracetamol
  • Indications Postoperative pain
  • Focus Therapeutic Use

Most Recent Events

  • 27 Dec 2018 New trial record
  • 12 Dec 2018 According to a Pacira Pharmaceuticals media release, patients were enrolled at Texas Children's Hospital Pavilion for Women between 2012 and 2015. The study was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice and the Declaration of Helsinki and approved by an Institutional Review Board (IRB).
  • 12 Dec 2018 Results presented in a Pacira Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top